A Multicentre Clinical Investigation to Assess Efficacy and Safety of Intra-articular Injections of Hyaluronic Acid Combined With Chondroitin Sulfate in Knee Osteoarthritis

Osteo Arthritis Knee Clinical Trial

Official title:

A Multicentre Clinical Investigation to Assess Efficacy and Safety of Intra-articular Injections of a New Viscosupplement Based on Hyaluronic Acid Combined With Chondroitin Sulfate in Patients With Knee Osteoarthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04358120
• Other study ID #: RR82-17-01
• Status: Completed
• Phase: N/A
• Start date: November 28, 2017
• Est. completion date: September 18, 2018

Study information

• Verified date: March 2020
• Source: Fidia Farmaceutici s.p.a.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicentre, prospective, sponsor initiated clinical investigation that aims to evaluate safety and efficacy of Hyaluronic Acid Combined With Chondroitin Sulfate in symptomatic patients with OA of the knee.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: September 18, 2018
• Est. primary completion date: September 18, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• At Screening

• Male or female between the ages of 40 and 80

• Body Mass Index (BMI) = 30;

• Mean knee pain score at rest over the last 24 hours evaluated on VAS (0-100) =

40. The most painful knee is considered the target knee;

• OA of the Knee radiologically and clinically confirmed responding to criteria of American College of Rheumatology (ACR): pain of the knee and crepitus on active motion or morning stiffness less than 30 minutes or age >50 years

• Symptomatic knee pain for more than 6 months;

• Radiological Kellgren and Lawrence grade II or III confirmed by an X-ray not older than 12 months;

• Willing to discontinue any systemic analgesic/NSAID therapy, opioids, systemic corticosteroids, skeletal muscle relaxants, and any other medication that would interfere with the study assessments, except for the rescue medication, with no intention to resume them during the clinical investigation (see Appendix 5 for wash out period);

• Patient able to comply with the instructions of the clinical investigation and to maintain a Rescue Medication Diary during the study;

• Having signed the study informed consent.

• at Baseline

• Patient does not have chondromatosis or villonodular synovitis of the knee evaluated by Ultrasound;

• Patient has complied with the requirements for rescue medication (no more than 6 tablets or 3 grams of paracetamol per day up to 4 days per week and paracetamol discontinued 24 hours before first IA injection);

• Mean knee pain score at rest over the last 24 hours evaluated on VAS (0 - 100) = 40 (with a washout period for Paracetamol of 24 hours);

• Patient has discontinued prior to Baseline the use of all prohibited medications in accordance with the washout period defined in Appendix 5;

• Patient continues to meet all Screening inclusion/exclusion criteria at the Baseline visit.

Exclusion Criteria:

• Related to the OA pathology

• Recent trauma (< 1 month) of the target knee responsible for the symptomatic knee pain;

• Articular disease resulting from articular dysplasia, aseptic osteonecrosis, acromegaly, Paget's disease, haemophilia, hemochromatosis;

• Inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, gout and infectious arthritis, acute calcium pyrophosphate arthritis);

• Pathologies interfering with the evaluation of OA. Related to treatments

• Corticosteroids injection in the target knee in the last 3 months before first intra-articular (IA) injection;

• Hyaluronan injection in the target knee in the last 6 months before first IA injection;

• Arthroscopy and surgery in the target knee in the last 3 months before first IA injection;

• Oral corticosteroid therapy = 5mg/day (in Prednisone equivalent) in the last 3 months before first IA injection;

• OA treatments based on curcuma extract in the last 3 months before first IA injection;

• Change in the dosage of symptomatic slow-acting drugs (SYSADOA) e.g., chondroitin, glucosamine, diacerein or avocado-soya unsaponifiables in the last 3 months before first IA injection;

• Contraindications to 4% GAG: hypersensitivity to the product components;

• Infections or skin diseases in the area of the injection site;

• Change in the dosage of ongoing non-pharmacologic therapy for the lower extremities (including physical therapy) initiated in the month before first injection;

• Anticoagulant (coumarinic compound) and heparin. Related to associated diseases

• Severe diseases (e.g., liver or renal failure, lung/heart disease, tumour, HIV);

• Severe alteration of mobility interfering with the functional evaluation;

• High risk of haemorrhage;

• Patient with known allergy to paracetamol;

• Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee.

Related to study subjects

• Participation to a therapeutic clinical trial in the last 3 months before first injection;

• Pregnancy, breastfeeding, planned conception and premenopausal women without contraception, tubal ligation or hysterectomy

Related Conditions & MeSH terms

• Osteo Arthritis Knee
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Device:
• Hyaluronic Acid Combined With Chondroitin Sulfate
Subjects' participation in the study will last 26 weeks. The study includes 7 visits that consist of a Screening visit, three treatment visits and three follow-up visits. Eligible subjects will undergo a Baseline visit (V1 at week 0) during which, after the confirmation of eligibility, assessments and ultrasound evaluation, the study subjects will be treated with the 1st injection of 2%Hyaluronic Acid and 2% chondroitin sulfate Subsequent treatments will be administered at weekly intervals during Visit 2 (V2 at week 1) and Visit 3 (Visit 3 at week 2) after the effectiveness assessments. Study subjects will return for Follow-up visits 1 month (Visit 4 at week 6), 3 months (Visit 5 at week 14) and 6 months (Visit 6 at week 26) after the last injection

Locations

Country	Name	City	State
Czechia	Revmacentrum MUDr. Mostera,	Brno
Czechia	Rheumatology, Polyclinic Lesná	Brno
Czechia	Institute of rheumatology	Prague
Czechia	University Hospital Motol, Department of Rheumatology of Children and Adults	Prague
Czechia	Medical Plus, s.r.o	Uherské Hradište

Sponsors (1)

Lead Sponsor	Collaborator
Fidia Farmaceutici s.p.a.

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in pain score measured by Visual Analogue Scale (VAS)	Change in pain perception from baseline in patient with knee osteoarthritis after three intra-articular 2% Chondroitin Sulfate + 2% hyaluronic Acid injections assessed by Visual Analogue Scale (VAS) (From 0 to 100) at weeks 6, 14 and 26	at week 6, 14 and 26
Secondary	Change in Patient's Global Assessment	Change from baseline up to 26 weeks after first treatment in Patient's Global Assessment of knee functional disability, assessed by VAS (0-100)	at weeks 6, 14 and 26
Secondary	Change from baseline in knee pain and function up to 26 weeks	Change from baseline provided by the intra-articular 2% Chondroitin Sulfate + 2% Hyaluronic Acid injections measured by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index (0-100 mm) for knee at weeks 6, 14 and 26	at weeks 6, 14 and 26
Secondary	Change from baseline up to 26 weeks after first treatment on knee functional disability on Clinical Observer Global Assessment (COGA)	Change from baseline up to 26 weeks after first treatment in COGA of knee functional disability, assessed by VAS (0-100)	at weeks 6, 14 and 26
Secondary	Number of patients Responder to treatment	Number of patients with clinical response to treatment using the OMERACT-OARSI set of criteria: high improvement in pain or function = 50% or improvement in at least 2 of the 3 of the following criteria: high improvement in pain or function = 50% or improvement in at least 2 of the 3 following: pain = 20% and absolute change =10,; function =20% and absolute change =10,; PGA = 20% and absolute change =10.	Weeks 6, 14 and 26
Secondary	Change from baseline in Synovitis at 6 weeks	Change in Synovitis at week 6 vs week 0 assessed by ultrasound scored according to the scoring systems proposed by OMERACT US on knee OA.; A global score for synovitis corresponds to the maximum score for synovitis obtained at the suprapatellar or parapatellar recesses.; Synovitis (grades 0-3): Grade 0 = no synovitis, Grade 1= minimal distension, Grade 2= moderate distension or enlargement, Grade 3= severe distension or enlargement of the recess	at week 6
Secondary	Change from baseline in Synovial hypertrophy at 6 weeks	Change in Synovial hypertrophy at week 6 vs week 0 assessed by ultrasound scored according to the scoring systems proposed by OMERACT US on knee OA.; Synovial hypertrophy (0-1) where 0= absence, 1= presence	at week 6
Secondary	Change from baseline in knee Effusion at 6 weeks	Change in Effusion at week 6 vs week 0 assessed by ultrasound scored according to the scoring systems proposed by OMERACT US on knee OA.; Effusion (0-1) 0= absence, 1= presence	at week 6
Secondary	Change from baseline in popliteal cyst at 6 weeks	Change in Popliteal cyst at week 6 vs week 0 assessed by ultrasound scored according to the scoring systems proposed by OMERACT US on knee OA.; Popliteal cyst (0-1) 0= absence, 1= presence	at week 6
Secondary	Change in Synovial Power Doppler signal at week 6	Changein Synovial Power Doppler signal at week 6 vs week 0 assessed by ultrasound.; Synovial Power Doppler signal (0-1) and (0-3) Grade 0 = no intra-articular colour signal Grade 1 = up to three signal colour signals or two single and one confluent colour signals representing only low flow	at week 6
Secondary	Safety of the treatment. Number of patient with treatment related adverse events	Safety evaluation by tracking the number of patient withdrawals and their adverse events correlated to treatment at each visit	through study completion